Clinical trial reporting still dangerously inadequate, says BMJ
This article was originally published in Scrip
The British Medical Journal (BMJ) has published seven research papers providing a damning indictment of current practice in clinical trial reporting. According to the accompanying editorial by senior research fellow Richard Lehman and clinical epidemiology editor Elizabeth Loder, the articles confirm that "a large proportion of evidence from human trials is unreported, and much of what is reported is done so inadequately". As they note, this leads to unnecessary harm to patients and costs to health systems.
You may also be interested in...
BioNTech extends Pfizer partnership to cover COVID-19 vaccine development and distribution while Fosun Pharma takes Chinese rights.
Dietmar Hopp, 80% shareholder of German mRNA company CureVac, has rejected the possibility that the company would sign an exclusive deal with the US for its investigational coronavirus vaccine.
Infographic: Scrip homes in on key figures for companies integrating major acquisitions or divesting significant parts of their business.